
    
      Eligible patients will be randomly assigned to FOLFOXiri group and FOLFOX group.
      Stratification factors include ECOG PS, disease extent and pathological subtypes. Efficacy
      will be evaluated every 3-4 cycles with RECIST. Toxicity will be assessed with WHO CTC 3.0
      every 2 weeks.
    
  